Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Cancer Immunotherapy Market

Cancer Immunotherapy Market Share

Report ID: GMI9584
Published Date: May 2024
Report Format: PDF

Download Free Sample

Cancer Immunotherapy Market Share

The cancer immunotherapy industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.

Cancer Immunotherapy Market Companies

Some of the eminent market participants operating in the cancer immunotherapy industry include:

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Celldex Therapeutics, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GSK plc
Immunocore Holdings plc
Johnson & Johnson
Merck & Co., Inc
Novartis AG
Pfizer Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of cancer immunotherapy reached USD 125.7 billion in 2023 and is set to witness 9.3% CAGR from 2024 to 2032, led by rising prevalence of cancer.

The monoclonal antibodies product segment will reach USD 119.6 billion in revenue by 2032, as they are designed to target specific proteins or antigens present on cancer cells.

U.S. market size will record USD 115.2 billion by 2032, owing to the presence of world-renowned research institutions, academic medical centers, and biopharmaceutical companies at the forefront of cancer immunotherapy research and innovation.

AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celldex Therapeutics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., and GSK plc among others.